Abstract
Fourteen children have undergone liver transplantation for hereditary tyrosinaemia type 1 (HT1) at Birmingham Children’s hospital (BCH) since 1989; six were treated prior to the availability of Nitisinone in 1993 and eight in the post Nitisinone era. Prior to 1993 essentially all children with HT1 were referred for transplantation. In the Nitisinone era only those with unresponsive liver failure or suspected malignancy were considered for transplantation. Those who were treated pre-emptively following newborn screening have no evidence of liver disease and none have required transplantation.
Absolute patient survival is 86% for the whole group and 100% in the Nitisinone era. There has been a functional correction of the metabolic defect in all cases allowing a normal diet. Persistent renal succinylacetone production was universal but did not appear to have any clinical consequence. Renal function appeared better, and hypertension less common in those treated in the Nitisinone era.
Outcome was poorer for those four children with established malignancy; one was unfit for transplantation and another developed a pulmonary metastasis, which was successfully resected.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Abbreviations
- AFP:
-
Alpha-fetoprotein
- cGFR:
-
Calculated glomerular filtration rate
- HB:
-
Hepatoblastoma
- HCC:
-
Hepatocellular carcinoma
- HT1:
-
Hereditary tyrosinaemia type 1
- PCR:
-
Protein:creatinine ratio
- SA:
-
Succinylacetone
- TRP:
-
Tubular reabsorption of phosphate
References
Bartlett DC, Lloyd C, McKiernan PJ, Newsome PN (2014) Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis 37(5):745–752
Bartlett DC, Preece MA, Holme E, Lloyd C, Newsome PN, McKiernan PJ (2013) Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1. J Inherit Metab Dis 36(1):15–20
Baumann U, Duhme V, Auth MK, McKiernan PJ, Holme E (2006) Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr 43(1):77–82
Buyukpamukcu M, Varan A, Haberal M, Buyukpamukcu N, Koksal Y, Coskun T, Yuce A, Kale G, Akyuz C, Kutluk T (2006) The efficacy of liver transplantation in malignant liver tumors associated with tyrosinemia: clinical and laboratory findings of five cases. Pediatr Transplant 10(4):517–520
Fisch RO, McCabe ER, Doeden D, Koep LJ, Kohlhoff JG, Silverman A, Starzl TE (1978) Homotransplantation of the liver in a patient with hepatoma and hereditary tyrosinemia. J Pediatr 93(4):592–596
Introne WJ, Perry MB, Troendle J, Tsilou E, Kayser MA, Suwannarat P, O'Brien KE, Bryant J, Sachdev V, Reynolds JC, Moylan E, Bernardini I, Gahl WA (2011) A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol Genet Metab 103(4):307–314
Larochelle J, Alvarez F, Bussieres JF, Chevalier I, Dallaire L, Dubois J, Faucher F, Fenyves D, Goodyer P, Grenier A, Holme E, Laframboise R, Lambert M, Lindstedt S, Maranda B, Melancon S, Merouani A, Mitchell J, Parizeault G, Pelletier L, Phan V, Rinaldo P, Scott CR, Scriver C, Mitchell GA (2012) Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 107(1–2):49–54
Mayorandan S, Meyer U, Gokcay G, Segarra N, de BH, van SF, Zeman J, de LC, Spiekerkoetter U, Thimm E, Maiorana A, Dionisi-Vici C, Moeslinger D, Brunner-Krainz M, Lotz-Havla A, Cocho de JJ, Couce PM, Santer R, Scholl-Burgi S, Mandel H, Bliksrud Y, Freisinger P, Aldamiz-Echevarria L, Hochuli M, Gautschi M, Endig J, Jordan J, McKiernan P, Ernst S, Morlot S, Vogel A, Sander J, Das A (2014) Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice. Orphanet J Rare Dis 9(1):107
Mazariegos G, Shneider B, Burton B, Fox IJ, Hadzic N, Kishnani P, Morton DH, McIntire S, Sokol RJ, Summar M, White D, Chavanon V, Vockley J (2014) Liver transplantation for pediatric metabolic disease. Mol Genet Metab 111(4):418–427
McKiernan PJ (2010) Long-term care following paediatric liver transplantation. Arch Dis Child Educ Pract Ed
McKiernan PJ (2013) Nitisinone for the treatment of hereditary tyrosinemia type I. Expert Opin Orphan Drugs 1(6):491–497
McKiernan PJ, Preece MA, Chakrapani A (2015) Outcome of children with hereditary tyrosinaemia following newborn screening. Arch Dis Child 100(8):738–741
Mohan N, McKiernan P, Preece MA, Green A, Buckels J, Mayer AD, Kelly DA (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158(Suppl 2):S49–S54
National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1–266
Nobili V, Jenkner A, Francalanci P, Castellano A, Holme E, Callea F, Dionisi-Vici C (2010) Tyrosinemia type 1: metastatic hepatoblastoma with a favorable outcome. Pediatrics 126(1):e235–e238
Pierik LJ, van Spronsen FJ, Bijleveld CM, van Dael CM (2005) Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 28(6):871–876
Santra S, Preece MA, Hulton SA, Mckiernan PJ (2008) Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 31(3):399–402
Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin N Am 34(3):571–590
Sokal EM, Bustos R, Van Hoof F, Otte JB (1992) Liver transplantation for hereditary tyrosinemia – early transplantation following the patient’s stabilization. Transplantation 54(5):937–939
Tuchman M, Freese DK, Sharp HL, Ramnaraine ML, Ascher N, Bloomer JR (1987) Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation. J Pediatr 110(3):399–403
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
McKiernan, P. (2017). Liver Transplantation for Hereditary Tyrosinaemia Type 1 in the United Kingdom. In: Tanguay, R. (eds) Hereditary Tyrosinemia. Advances in Experimental Medicine and Biology, vol 959. Springer, Cham. https://doi.org/10.1007/978-3-319-55780-9_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-55780-9_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-55779-3
Online ISBN: 978-3-319-55780-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)